Saturday 17 October 2026
Export STLN’s income statement to Excel — free account
Starling Oncology, Inc.
STLN Healthcare Medical Care Facilities
Starling Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $502.7 million, up 27.8% from fiscal 2024. In the quarter to June 2026, revenue grew 34.6%, EPS grew 46.7%, free cash flow grew 196.7% and total debt rose 6.46%, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three; insiders bought in the last twelve months.
6.43
0.48
−6.95%
Follow STLN
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.74 | 0.65 | 0.57 | 0.95 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(26.93) | 101.73 | (141.10) | 46.86 | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
0.84 | 0.74 | 0.66 | 1.02 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(16.46) | (15.17) | (16.55) | 1,824.43 | |
EV/FCF |
(14.13) | (13.42) | (14.03) | (182.11) | |
Quick Ratio |
1.34 | 1.31 | 1.13 | 1.14 | |
Current Ratio |
1.68 | 1.59 | 1.47 | 1.36 | |
Net Debt/EBITDA |
(9.41) | (10.77) | (13.11) | (25.47) | |
Debt/Assets |
46.57% | 47.01% | 46.73% | 44.81% | |
Debt/Equity |
(6.21) | (4.92) | (4.83) | (3.21) | |
Asset Turnover |
2.69 | 2.98 | 3.29 | 3.47 | |
Operating CF/Net income |
0.77 | (0.43) | 0.89 | (1.22) | |
Capex/Depreciation |
(0.21) | (0.37) | (0.37) | (0.29) | |
Interest Coverage |
(4.19) | (3.60) | (3.37) | (2.48) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
18.49% | 19.75% | 19.13% | 18.57% | |
Intangible Assets out of Total Assets |
0.12 | 0.11 | 0.10 | 0.09 | |
Share Based Compensation of Revenue |
0.75% | 0.93% | 1.14% | 0.66% | |
Graham Net Nets |
(0.19) | (0.21) | (0.22) | (0.13) | |
Graham Number |
1.35 | 1.46 | 1.15 | 1.28 | |
Earnings Yield |
(18.34%) | (15.73%) | (12.05%) | (5.52%) | |
Free Cash Flow Yield |
(8.09%) | (8.45%) | (8.23%) | (0.59%) | |
Revenue per Share |
1.40 | 1.54 | 1.45 | 1.57 | |
Operating CF per Share |
(0.13) | 0.04 | (0.02) | 0.12 | |
Capex per Share |
(0.01) | (0.01) | (0.01) | (0.01) | |
Free Cash Flow per Share |
(0.14) | 0.02 | (0.03) | 0.11 | |
Cash per Share |
0.28 | 0.36 | 0.30 | 0.40 | |
Shareholders Equity per Share |
(0.13) | (0.17) | (0.16) | (0.24) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(0.13) | (0.17) | (0.16) | (0.24) | |
Free Cash Flow |
(13.23) | 2.17 | (3.26) | 11.03 | |
Working Capital |
44.51 | 41.79 | 37.51 | 34.05 | |
Capital Expenditures |
(0.60) | (1.06) | (1.04) | (0.91) | |
Net Current Asset Value |
(65.80) | (67.63) | (67.65) | (74.16) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.01 | 0.01 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
57.42 | 54.00 | 54.56 | 61.32 | |
Average Payables |
30.10 | 33.75 | 38.47 | 47.61 | |
Average Inventory |
14.49 | 13.46 | 18.30 | 17.90 | |
Average Assets |
171.40 | 168.69 | 166.12 | 169.02 | |
Average Common Equity |
1.60 | (6.07) | (5.61) | (16.95) |
Columns are period end dates